Evidence map›Paper›PMID 42017474›Full record

ReviewFuture oncology (London, England)2026

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.

Jinyong Kim, Myung-Ju Ahn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jinyong KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-9153-8513
Myung-Ju AhnDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-5740-9654

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HER2 mutations define a distinct molecular subset of non-small cell lung cancer (NSCLC) associated with poor outcomes and limited benefit from conventional systemic therapies. Zongertinib is a next-generation, HER2-selective irreversible tyrosine kinase inhibitor (TKI) designed to spare wild-type EGFR and improve tolerability. Zongertinib has demonstrated clinically meaningful systemic and intracranial activity with a manageable safety profile across multiple cohorts in the phase Ia/Ib Beamion LUNG-1 study, including previously treated, treatment-naïve, post-HER2 antibody-drug conjugate (ADC), non-tyrosine kinase domain mutation, and brain metastases populations. This review summarizes the pharmacologic rationale, clinical efficacy, safety, biomarker analyses, and ongoing phase III development of zongertinib in HER2-mutant NSCLC.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungErb-b2 Receptor Tyrosine KinasesLung NeoplasmsMutationProtein Kinase InhibitorsPyrazolesAcrylamidesBrain NeoplasmsHumansImidazolesPyrimidinesTreatment OutcomeAcrylamidesAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImidazolesProtein Kinase InhibitorsPyrazolesPyrimidineszongertinibbrain metastasisHER2-mutant NSCLCHER2-selective tyrosine kinase inhibitortargeted therapyZongertinib

Identifiers

PMID42017474
PMCPMC13154961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.